Sugi Predict

Sugi Predict / Compounds / SCHEMBL694700

SCHEMBL694700

SCHEMBL694700

O=C(O)C1(c2ccc(Cl)cc2)CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AKR1C1 Q04828 1/20 0.66
▸ HDAC4 P56524 2/20 0.64
▸ HSD11B1 P28845 8/20 0.63
▸ MAP4K4 O95819 1/20 0.57
▸ KMT2A Q03164 2/20 0.56
▸ TET3 O43151 1/20 0.56
▸ FBXL19 Q6PCT2 1/20 0.56
▸ CXXC5 Q7LFL8 1/20 0.56
▸ KDM2B Q8NHM5 1/20 0.56
▸ CXXC4 Q9H2H0 1/20 0.56
▸ KDM2A Q9Y2K7 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.54
▸ MEN1 O00255 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ HDAC1 Q13547 1/20 0.49
▸ FFAR2 O15552 1/20 0.48
▸ SLC6A4 P31645 1/20 0.46
▸ SLC6A3 Q01959 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503762 0.98 AKR1C1 (0.68) AKR1C1HDAC4HSD11B1MAP4K4KMT2A
Hydrochloric Acid SCHEMBL5741878 0.96 AKR1C1 (0.66) AKR1C1HDAC4HSD11B1MAP4K4KMT2A
SCHEMBL1794 0.94 AKR1C1 (0.62) AKR1C1HDAC4HSD11B1MAP4K4KMT2A
SCHEMBL75310 0.90 TET3 (0.61) AKR1C1HDAC4HSD11B1MAP4K4KMT2A
SCHEMBL4805246 0.85 HDAC4 (0.64) AKR1C1HDAC4HSD11B1MAP4K4ALDH1A1
SCHEMBL12020281 0.83 HDAC4 (0.62) HDAC4HSD11B1ALDH1A1HDAC1FFAR2
SCHEMBL11029291 0.83 HDAC4 (0.62) AKR1C1HDAC4HSD11B1MAP4K4ALDH1A1
SCHEMBL17253129 0.83 HDAC4 (0.62) AKR1C1HDAC4HSD11B1MAP4K4ALDH1A1
SCHEMBL9577271 0.83 HDAC4 (0.62) AKR1C1HDAC4HSD11B1MAP4K4ALDH1A1
SCHEMBL1627734 0.82 HDAC4 (0.66) AKR1C1HDAC4HSD11B1MAP4K4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673883-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-06-13 — — US claimed
CN-111517905-B Synthesis method of trans-4- (4-alkenyl cyclohexyl) -1,1' -biphenyl compound 西安瑞联新材料股份有限公司 2022-08-02 — — CN claimed
EP-3464279-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2021-11-24 — — EP claimed
CN-111517905-A Synthesis method of trans-4- (4-alkenyl cyclohexyl) -1,1' -biphenyl compound 西安瑞联新材料股份有限公司 2020-08-11 — — CN claimed
EP-3464279-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2019-04-10 — — EP claimed
US-20170342060-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-30 — — US claimed
WO-2017205464-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-11-30 — — WO claimed
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS NATIONAL HEALTH RES INST (TW) 2026-02-19 — — US disclosed
US-RE50453-E1 Indole derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-10 — — US disclosed
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2024-03-21 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
US-6200976-B1 FOR TREATING THROMBOSIS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-13 — — US disclosed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 — — WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
EP-0564924-B1 2-Oxoethyl derivatives as immunosuppressants BAYER AG (US) 1998-09-09 — — EP disclosed
US-5686424-A FOR TREATING INFLAMMATION MILES INC. (US) 1997-11-11 — — US disclosed
EP-0564924-A2 2-Oxoethyl derivatives as immunosuppressants Bayer Corporation (US) 1993-10-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342060-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS AKR1C1 1061/4885HDAC4 987/4885HSD11B1 1438/4885
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS OPRK1, OPRD1, OPRM1 AKR1C1 2084/4885HDAC4 2982/4885HSD11B1 1479/4885
US-11673883-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS AKR1C1 1061/4885HDAC4 987/4885HSD11B1 1438/4885
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B AKR1C1 3441/4885HDAC4 1752/4885HSD11B1 3556/4885
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 AKR1C1 1131/4885HDAC4 2932/4885HSD11B1 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.